Showing 4 posts of 4 posts found.


Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal

September 5, 2019
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma

Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …


Amgen’s novel KRAS inhibitor monotherapy shows promise at Phase 1 in advanced solid tumours

June 4, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, KRAS

Amgen has unveiled the first clinical data for its investigational KRAS inhibitor AMG 510, the first such therapy to reach …


AZ secures rights from Ionis for first-ever antisense KRAS cancer drug in $165m deal

December 19, 2016
Research and Development, Sales and Marketing AstraZeneca, Ionis, KRAS

AstraZeneca has paid a $28 million milestone payment in its partnership with Ionis Pharmaceuticals over the licensing rights to anticancer …

FDA approves Bayer’s Stivarga

October 1, 2012
Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin

The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …

Latest content